Article in Journal of human hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Jesse E PassmanDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jesse.passman@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-6599-0397
Amanda BaderDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nadim MahmudDivision of Gastroenterology, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kristoffel R DumonDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Heather WachtelDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Feibi ZhengGlobal Health Economics & Outcomes Research, Intuitive, Sunnyvale, CA, USA.
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Targeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEFR01HL155599 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.9M
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 SurvivorsR01HL157108 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA, Jordana B. Cohen · 2022 to 2026
$3.9M
Multidrug Metabolic Approach to Improve Exercise and Skeletal Muscle Oxidative Capacity in HFpEFR01HL157264 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.5M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2M
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical CentersU01HL160277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA · 2021 to 2026
$1.7M
A genotype-phenotype study of germline succinate dehydrogenase pathogenic variantsK08CA270385 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Heather Wachtel · 2022 to 2026
$967k
American Heart Association (American Heart Association, Inc.) Bugher AwardNCI NIH HHS K08 CA270385NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R01 HL155599NHLBI NIH HHS R01 HL157108NHLBI NIH HHS R01 HL157264NHLBI NIH HHS U01 HL160277NIDDK NIH HHS U24 DK060990U.S. Department of Health & Human Services | National Institutes of Health (NIH) K08-CA270385U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL153646U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL155599U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL157108U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-HL157264U.S. Department of Health & Human Services | National Institutes of Health (NIH) U01-HL160277U.S. Department of Health & Human Services | National Institutes of Health (NIH) U24-DK060990
6 · The paper itself
Abstract
Metabolic and bariatric surgery (MBS) is an effective treatment for obesity and metabolic syndrome. Evidence regarding the impact of MBS on hypertension outcomes is limited by short-term follow-up. Thus, this retrospective cohort study was designed to compare blood pressure (BP) control, number of antihypertensive medications (AHMs), development of apparent treatment resistant hypertension (ATRH), and remission of hypertension between patients treated with and without MBS. Adults with BMI ≥ 35 kg/m
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Effect of Bariatric Surgery on Hypertension Outcomes: A Retrospective Cohort Study. · full record | OpenQuestion